Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | LTK | P29376 | 1/20 | 0.53 |
| ▸ | MST1R | Q04912 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.44 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914266 | 1.00 | PARP1 (0.68) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL7581623 | 0.81 | PARP1 (1.00) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL1333209 | 0.78 | KDR (0.57) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL6297545 | 0.78 | PARP1 (0.70) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL29532218 | 0.78 | PARP1 (0.70) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL13964372 | 0.77 | PARP1 (0.50) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL24148319 | 0.76 | CDK5 (0.61) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL2379452 | 0.76 | CDK5 (0.61) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL1078443 | 0.76 | CDK5 (0.61) | PARP1CDK5DYRK1ACLK4PIM1 | |
| SCHEMBL9475196 | 0.76 | PARP1 (0.68) | PARP1CDK5DYRK1ACLK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-11-16 | — | — | US | claimed |
| WO-2022165185-A9 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2022165185-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| US-12215105-B2 | HPK1 antagonists and uses thereof | Nimbus Saturn, Inc. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114945366-B | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4393547-A2 | METHODS FOR DOSING AND TREATMENT OF B CELL MALIGNANCIES IN ADOPTIVE CELL THERAPY | Juno Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20240131173-A1 | PROTACS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-4327878-A2 | COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND | Juno Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003093249-A1 | THIAZOLIDINONES AND THE USE THEREOF AS POLO-LIKE KINASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030149050-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | INOTEK CORP. | 2003-08-07 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-6534651-B2 | Substituted isoindolinone derivatives | INOTEK PHARMACEUTICALS CORP. | 2003-03-18 | — | — | US | disclosed |
| US-20020095044-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2002-07-18 | — | — | US | disclosed |
| WO-2001077075-A2 | INHIBITORS OF INFLAMMATION AND REPERFUSION INJURY | INOTEK CORPORATION (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020095044-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | IL1B, PTGS1, MMP8 | PARP1 505/4885CDK5 411/4885DYRK1A 3592/4885 |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | ADRM1, MYC, SKP2 | PARP1 1231/4885CDK5 101/4885DYRK1A 3095/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | PARP1 758/4885CDK5 504/4885DYRK1A 2254/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | PARP1 3854/4885CDK5 4141/4885DYRK1A 4096/4885 |
| US-20030149050-A1 | Inhibitors of inflammation and reperfusion injury and methods of use thereof | IL1B, PTGS1, MMP8 | PARP1 505/4885CDK5 411/4885DYRK1A 3592/4885 |
| US-20240131173-A1 | PROTACS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES | VHL, UBTF, RELA | PARP1 1503/4885CDK5 514/4885DYRK1A 1307/4885 |
| US-12215105-B2 | HPK1 antagonists and uses thereof | PDXK, HIPK1, PCK1 | PARP1 2477/4885CDK5 934/4885DYRK1A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.